I will address your comments. For starters I have a MATERIAL LONG position and I read about your concerns and why you consider this to be a risky investment. I appreciate your having done your homework and do value negative critical analysis as it does put a certain amount of balance into an analysis. That being said Penny, I have dismissed your concerns as irrelevant since FDA had clearly disagreed without your concerns and has encouraged ETRM to file a PMA for its VBLOC. The FDA is serious about approving this device taking the time to get a panel of doctors to look at it, the FDA Panel.
Now ETRM went to visit FDA prior to filing their PMA. What do you think they discussed? ETRM must have shown them their results, which you are not satisfied with, and told them to go ahead and file.
The market for VBLOC is the U.S.A. where 69% of the people are overweight to obese. VVUS, ARNA and OREX which are pills are all targeting a multi billion dollar market. VBLOC will be different however so it is good for patients to have options.
The USA spends $ 147 billion per year treating these fat people for all sorts of medical problems due to ill health so the FDA is inclined to approve. They approved VVUS pill which is so dangerous because they really need help.
Since you have no position in this stock, it is unfair of you to either pump or bash, since it is really none of your business what I do with my investment and, I did not hire you as my counselor. If you hang around because you are a paid basher then I suggest you find better employment which is good for your soul since being the master of deception is the devils work.
Now I have answered your politely and I think all others on this board agreed, we heard you, thank-up for your comments, but please move on as your points are dismissed as irrelevant.
Drop the dark pooling trading words so yahoo monitors do not check it and just tell us why we are going up soon. Do you see a big buy order? I am expecting a jump in share price based on Material events which will be unfolding.